Icosapent ethyl is a prescription medication used to lower very high triglycerides and to reduce the risk of heart attacks, strokes, and other cardiovascular events in people already taking a statin. Sold under the brand name Vascepa, it contains a highly purified form of EPA, one of the omega-3 fatty acids found in fish oil, but in a concentrated pharmaceutical-grade formulation that works differently from store-bought supplements.
Lowering Very High Triglycerides
The original use of icosapent ethyl is for adults with severely elevated triglycerides, typically 500 mg/dL or higher. At these levels, triglycerides pose a risk not only for heart disease but also for pancreatitis, a painful and potentially dangerous inflammation of the pancreas. The medication works by reducing the liver’s production of triglyceride-rich particles that circulate in the blood. In clinical studies, it significantly lowered concentrations of large VLDL particles (the main triglyceride carriers) by about 28% and reduced small, dense LDL particles by roughly 26%.
One notable advantage over other omega-3 prescriptions that contain DHA is that icosapent ethyl does not raise LDL cholesterol. A meta-analysis of randomized trials confirmed it has no significant effect on LDL levels, which matters because raising LDL would undercut the goal of lowering cardiovascular risk.
Reducing Cardiovascular Events
The larger and more consequential use of icosapent ethyl is for cardiovascular risk reduction. This indication is based on the REDUCE-IT trial, which enrolled over 8,000 patients who were already on statin therapy but still had elevated triglycerides between 135 and 499 mg/dL. These patients either had established heart disease or were at least 50 years old with diabetes plus an additional risk factor like high blood pressure, smoking, or low HDL cholesterol.
The results were striking. Among patients who had recently experienced an acute coronary event (like a heart attack or unstable angina), icosapent ethyl reduced the combined risk of cardiovascular death and nonfatal heart attack by 36%. It also cut the need for urgent or emergency procedures to reopen blocked arteries by 44%. These reductions held up across a range of patient subgroups and went well beyond what triglyceride lowering alone would explain, suggesting the drug has anti-inflammatory or plaque-stabilizing effects on top of its lipid-lowering action.
Who Qualifies for Treatment
The National Lipid Association recommends icosapent ethyl for two broad groups of patients. The first includes adults aged 45 or older who already have atherosclerotic cardiovascular disease, meaning they’ve had a heart attack, stroke, or have documented artery blockages. The second includes adults aged 50 or older with medication-treated diabetes who also have at least one additional cardiovascular risk factor.
In both groups, the patient should already be taking a high-intensity or maximum-tolerated statin, and their fasting triglycerides should fall between 135 and 499 mg/dL. The additional risk factors that qualify someone with diabetes include being a current or recent smoker, having high blood pressure, low HDL cholesterol (40 mg/dL or below in men, 50 or below in women), kidney impairment, or signs of vascular or diabetic complications like retinopathy or an abnormal ankle blood pressure reading.
How It Differs From Fish Oil Supplements
Icosapent ethyl contains only EPA in a purified ethyl ester form. Over-the-counter fish oil capsules contain a mix of EPA and DHA in varying, often inconsistent amounts, along with other fatty acids and sometimes saturated fat. The concentration matters: achieving the 4-gram daily dose of pure EPA used in clinical trials would require taking a large and impractical number of standard fish oil capsules, and the therapeutic effects seen in REDUCE-IT have not been replicated with generic fish oil supplements.
There is also an absorption difference. The ethyl ester form in icosapent ethyl requires fat from a meal to be properly absorbed. Your body needs bile-triggered enzymes to break the bond between the fatty acid and the ester, so taking the capsules on an empty stomach significantly reduces how much EPA gets into your bloodstream. This is why the prescribing label specifies taking it with food. Newer free fatty acid formulations of omega-3s are less dependent on meal timing, but icosapent ethyl remains the only form with large-scale trial data showing cardiovascular benefit.
Dosing
The standard dose is 4 grams per day, split into two doses taken with meals. This can be taken as two 1-gram capsules twice daily or four 0.5-gram capsules twice daily. The dose is the same whether the goal is lowering severe triglycerides or reducing cardiovascular risk.
Side Effects Worth Knowing About
The most clinically meaningful side effects involve heart rhythm changes and bleeding. In the REDUCE-IT trial, 5.3% of patients on icosapent ethyl developed atrial fibrillation or flutter, compared to 3.9% on placebo. Hospitalizations for atrial fibrillation were also higher: 3.1% versus 2.1%. This is a real and measurable risk, particularly relevant for people who already have risk factors for irregular heart rhythms.
Bleeding is the other concern. In the same trial, 12% of patients taking icosapent ethyl experienced some type of bleeding event, compared to 10% on placebo. Serious bleeding occurred in 3% of the treatment group versus 2% on placebo. The risk was higher in patients also taking blood thinners or antiplatelet drugs like aspirin, clopidogrel, or warfarin. If you’re on any of these medications, your doctor will likely monitor you more closely for signs of unusual bruising or prolonged bleeding.
Common but less serious side effects include joint pain and muscle or bone discomfort. Gastrointestinal symptoms like constipation or gout flares have also been reported, though they’re relatively uncommon.